Dr Reddy's Laboratories on Thursday said it has launched the first generic version of Vimovo tablets, used to treat rheumatoid arthritis, in the US market.
The Hyderabad-based firm announced the first-to-market launch of Naproxen and Esomeprazole Magnesium delayed-release tablets in the US market, Dr Reddy's Laboratories Ltd (DRL) said in a statement.
The company's product is the generic version of Vimovo tablets approved by the US Food and Drug Administration (USFDA).
"This launch is a testament to our core strengths in areas of research and development and intellectual property," DRL North America Generics CEO Marc Kikuchi said.
He further said: "We are excited to be a part of forming the first generic market for Vimovo tablets and to provide an affordable treatment alternative for patients."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app